Saluda Medical, Inc. (ASX:SLD) disclosed that all three resolutions put to stockholders at its 2026 Annual Meeting of Stockholders, held on 18 November 2026 AEDT, were passed by way of a poll, including the election of two Class I Directors and approval of a 10% Placement Facility.

Key Points

  • All three resolutions at the 2026 Annual Meeting of Stockholders were decided and passed by poll on 18 November 2026 AEDT (17 November 2026 U.S. Central Time).
  • Mr Robert Faulkner was elected as a Class I Director with 15,179,460 votes in favour, representing 99.96% of votes cast.
  • Dr Geoffrey Brooke M.B.B.S. was elected as a Class I Director with 15,179,460 votes in favour, also representing 99.96% of votes cast.
  • The 10% Placement Facility was approved with 15,157,611 votes in favour, representing 99.82% of votes cast, with 20,196 votes against (0.13%) and 7,863 abstentions.

Election of Class I Directors Robert Faulkner and Geoffrey Brooke

Stockholders voted to elect two Class I Directors at the meeting. Mr Robert Faulkner received 15,179,460 votes in favour, equating to 99.96% of votes cast, with zero votes against and 6,210 abstentions. Dr Geoffrey Brooke M.B.B.S. received an identical vote count, with 15,179,460 votes in favour at 99.96%, zero votes against, and 6,210 abstentions. Both resolutions were decided by poll, as disclosed in the results filed under ASX Listing Rule 3.13.2.

Approval of 10% Placement Facility

The third resolution, seeking approval of a 10% Placement Facility, was passed by poll with 15,157,611 votes in favour, representing 99.82% of votes cast. A total of 20,196 votes were recorded against the resolution, equating to 0.13%, while 7,863 votes were recorded as abstentions, representing 0.05%. The resolution was passed at the same meeting held on 18 November 2026 AEDT, corresponding to 17 November 2026 U.S. Central Time.

Company Background and CDI Foreign Ownership Restriction

Saluda Medical is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using a neuromodulation platform. The company's CHESS Depositary Interests (CDIs) are issued in reliance on Regulation S under the U.S. Securities Act of 1933. The company disclosed that CDI holders may not offer, sell, pledge, or otherwise transfer CDIs into the United States or to a U.S. Person for a period of at least 12 months from the allotment date under the IPO, unless registration or an applicable exemption is available. The meeting results were authorised for release by Saluda Medical's Disclosure Committee.